November, 13 2019 08:00 AM | GlobeNewswire |
ATLANTA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the
management of retinal diseases, announces that it has terminated
its $20.0 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), effective November 12, 2019.
“After assessing our expectations for the remainder of this year
and plans for 2020,
we have made the decision to terminate our equity purchase agreement.
Having completed the third quarter of 2019 at an annualized revenue
run rate in excess of $50 million,
we believe we have sufficient cash on hand to fund our operations throughout 2020,” said Rick Eiswirth, president and CEO of Alimera.
“Currently we believe that our common stock is
significantly undervalued
and we have no plans to issue equity at these levels.
We continue to expand the usage of ILUVIEN both domestically and internationally and believe the best course of action is to continue
to execute this plan without further dilution to our stockholders at this time.
We appreciate the commitment from LPC and their initial investment of $1.0 million.”
Other than the initial investment,
Alimera has not requested any additional purchases under the agreement.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization
and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases.
Alimera is presently focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.
For more information, please visit http://www.alimerasciences.com.
About ILUVIEN
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant,
injected into the back of the eye.
With its CONTINUOUS MICRODOSINGTM technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide,
a corticosteroid,
for up to 36 months,
to reduce the recurrence of disease,
enabling patients to maintain vision longer with fewer injections.
ILUVIEN is approved in the
U.S.,
Canada,
Kuwait,
Lebanon and
the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated
with chronic DME considered insufficiently responsive to available therapies.
In March 2019, ILUVIEN received approval in the
17 countries under the Mutual Recognition Procedure for prevention
of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
The 17 European countries include the U.K., Germany, France, Italy,
Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland,
Sweden, Poland, Czech Republic, the Netherlands, and Luxembourg.
The regulatory process is now in the national phase in which the European member states have finalized or are expected to finalize the label for the new indication to meet each country’s local requirements.
Timeline to this goal varies by each country. ILUVIEN is not approved for treatment of uveitis in the United States.
Forward-Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, Alimera’s expectations that it has sufficient cash on hand to fund its operations throughout 2020, its belief that it has no plans to issue equity at the current trading price of its common stock, its expectations regarding its expansion of the usage of ILUVIEN both domestically and internationally and its belief that the best course of action is to continue to execute this plan without further dilution to its stockholders at this time. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change them, and could cause actual results to differ materially from those projected in the forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to, (a) a slowdown or reduction in Alimera’s sales in due to a reduction in end user demand, unanticipated competition, regulatory issues, or other unexpected circumstances; and (b) other factors discussed in the “Special Note Regarding Forward-Looking Statements and Projections,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2018, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019, which are on file with the Securities and Exchange Commission and available on its website at http://www.sec.gov.
For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com
For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com
Recent ALIM News
- Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/08/2024 10:23:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:32:14 PM
- Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 03/07/2024 12:30:00 PM
- Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:43:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:24:52 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 08:27:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/09/2024 10:25:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/09/2024 10:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:08:13 PM
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN® • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 05:49:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:02:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:02:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:17 PM
- Alimera Completes Recruitment for the Synchronicity Study • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 10:20:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 10:09:52 PM
- Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/12/2023 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM